Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

doi:10.3350/cmh.2021.0155

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23520

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23520

Title:	Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Authors:	Liu, CH;Chen, CY;Su, WW;Liu, CJ;Lo, CC;Huang, KJ;Chen, JJ;Tseng, KC;Chang, CY;Peng, CY;Shih, YL;Huang, CS;Kao, WY;Yang, SS;Tsai, MC;Wu, JH;Chen, PY;Su, PY;Hwang, JJ;Fang, YJ;Lee, PL;Tseng, CW;Lee, FJ;Lai, HC;Hsieh, TY;Chang, CC;Chang, CH;Huang, YJ;Kao, JH
Keywords:	Hepatitis;Chronic;Antiviral agents;Sofosbuvir;Ribavirin;Liver cirrhosis
Date:	2021
Issue Date:	2022-08-05T09:38:36Z (UTC)
Publisher:	KOREAN ASSOC STUDY LIVER
ISSN:	2287-2728
Abstract:	Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR12) for the evaluable population (EP), modified EP, and per-protocol population (PP) were assessed. The safety profiles were reported. Results: The SVR12 rates in the EP, modified EP and PP were 89.7% (95% confidence interval [CI], 82.5-94.2%), 94.1% (95% CI, 87.8-97.3%), and 100% (95% CI, 96.2-100%). Number of patients who failed to achieve SVR12 were attributed to virologic failures. The SVR12 rates were comparable regardless of patient characteristics. One patient discontinued treatment because of adverse events (AEs). Twenty-four patients had serious AEs and six died, but none were related to SOF/VEL or RBV. Among the 96 patients achieving SVR12, 84.4% and 64.6% had improved Child-Pugh and model for end stage liver disease (MELD) scores. Multivariate analysis revealed that a baseline MELD score >_15 was associated with an improved MELD score of >_3 (odds ratio, 4.13; 95% CI, 1.16-14.71; P=0.02). Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate declines than patients with CKD stage 2 (-0.42 mL/min/1.73 m(2)/month; P=0.01) or stage 3 (-0.56 mL/min/1.73 m(2)/month; P<0.001). Conclusions: SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis.
URI:	http://dx.doi.org/10.3350/cmh.2021.0155 https://www.webofscience.com/wos/woscc/full-record/WOS:000706507200008 https://ir.csmu.edu.tw:8080/handle/310902500/23520
Relation:	CLINICAL AND MOLECULAR HEPATOLOGY ,2021,v27,issue 4, P575-588
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	233	View/Open

Loading...